What's Happening

A biosimilar of Stelara^®, this drug is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis

A long-acting, atypical antipsychotic indicated for the treatment of schizophrenia

A first-in-class biologic indicated for the treatment of pulmonary arterial hypertension to increase exercise capacity and reduce the risk of clinical worsening events

Indicated for the treatment of pulmonary arterial hypertension, both in patients who are treatment naïve or who are already on an ERA, PDE5 inhibitor or both

Indicated for the treatment of hypertension in combination with other antihypertensive drugs to lower blood pressure

A biosimilar to Humira, this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, and plaque psoriasis

Indicated for the treatment of HIV-1 infection

Indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate

Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults, or overweight adults with at least one weight-related comorbidity

Indicated as an adjunct to diet and exercise to improve glycemic control of type 2 diabetes

Indicated for erosive esophagitis and the relief of heartburn associated with erosive esophagitis

Indicated for the maintenance treatment of moderate to severe ulcerative colitis or moderate to severe Crohn’s disease, following treatment with an infliximab product administered intravenously

A first-in-class agent indicated for the treatment of moderate to severe ulcerative colitis

A biosimilar to Stelara, indicated for the treatment of moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis